Alzamend Neuro ALZN
NASDAQ ALZN
$1.67 -0.04 (-2.34%)
As of: Sep 10, 2026 · 12:03 PM EDT

Alzamend Neuro (ALZN) Income towards Parent Company (2020 - 2026)

Alzamend Neuro's (ALZN) quarterly Income towards Parent Company came in at -$2.9 million in Q2 2026, down 151.97% year-over-year from $5.5 million in Q2 2025, and down 30.56% quarter-over-quarter from -$2.2 million in Q1 2026.

Analysis

Alzamend Neuro (ALZN) Income towards Parent Company (2020 - 2026) Analysis & Trends

Alzamend Neuro has disclosed Income towards Parent Company across 7 years of filings, most recently posting -$2.9 million for Q2 2026.

  • In Q2 2026, Income towards Parent Company fell 151.97% year-over-year to -$2.9 million; the TTM figure through Apr 2026 stood at -$8.8 million (down 92.04% YoY), while the FY2026 annual figure was -$8.8 million, down 94.3% from the prior year.
  • Income towards Parent Company came in at -$2.9 million for Q2 2026 at Alzamend Neuro, down from -$2.2 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$851529.0 in Q2 2024 to a low of -$5.4 million in Q1 2023.
  • Average Income towards Parent Company over 5 years is -$2.5 million, with a median of -$2.7 million recorded in 2024.
  • Year-over-year, Income towards Parent Company plunged 208.83% in 2022 and soared 74.24% in 2024.
  • Over 5 years, Income towards Parent Company stood at -$3.1 million in 2022, then rose by 6.56% to -$2.9 million in 2023, then jumped by 51.3% to -$1.4 million in 2024, then grew by 29.29% to -$1.0 million in 2025, then plunged by 186.89% to -$2.9 million in 2026.
  • Per Business Quant data, the three most recent Income towards Parent Company figures were -$2.9 million in Q2 2026, -$2.2 million in Q1 2026, and -$1.0 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.86 Bn 192.87 Bn 7.24 Bn
2 Gilead Sciences 179.52 Bn 176.34 Bn 6.22 Bn
3 Vertex Pharmaceuticals 131.47 Bn 123.62 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 61.16 Bn 55.98 Bn 1.37 Bn
6 Moderna 53.15 Bn 48.02 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.20 Bn 29.89 Bn 992.69 Mn
8 Biogen 31.65 Bn 30.37 Bn 1.96 Bn
9 Roivant Sciences 29.30 Bn 29.30 Bn 1.16 Mn
10 Alzamend Neuro 5.57 Mn 5.57 Mn -
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2026 -2.87 Mn
Jan 31, 2026 -2.20 Mn
Oct 31, 2025 -1.00 Mn
Jul 31, 2025 -2.70 Mn
Apr 30, 2025 -1.14 Mn
Jan 31, 2025 -1.04 Mn
Oct 31, 2024 -1.42 Mn
Jul 31, 2024 -974,411.00
Apr 30, 2024 -851,529.00
Jan 31, 2024 -2.66 Mn
Oct 31, 2023 -2.91 Mn
Jul 31, 2023 -3.53 Mn
Apr 30, 2023 -3.31 Mn
Jan 31, 2023 -5.43 Mn
Oct 31, 2022 -3.11 Mn
Jul 31, 2022 -3.04 Mn
Apr 30, 2022 -3.87 Mn
Jan 31, 2022 -2.57 Mn
Oct 31, 2021 -3.60 Mn
Jul 31, 2021 -2.32 Mn